QGEN: Future Results Will Depend On Automation And Gradual Sentiment Recovery

AN

AnalystConsensusTarget

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

23 Aug 24

Updated

14 Dec 25

Views

61

n/a

n/a

AnalystConsensusTarget's Fair Value

n/a

1Y

-2.6%

7D

-0.9%

Loading

1Y

-2.6%

7D

-0.9%

You can edit this narrative until Dec 15 10:05 AM. Then, changes will post as Updates.

Author's Valuation

US$50.439.9% undervalued

AnalystConsensusTarget Fair Value

Shared on 14 Dec 25

Fair value Decreased 0.70%

QGEN: Stable End Markets Will Support Gradual Sentiment Recovery Ahead

Analysts have trimmed their price target on Qiagen slightly, with a modest fair value reduction of about $0.36 per share. They cite still stable end markets, expectations for gradual improvement ahead, and a view that investment sentiment and valuations have largely bottomed.

Shared on 29 Nov 25

QGEN: Gradual Improvement Ahead As End Markets Remain Stable And Sentiment Bottoms

Analysts have modestly lowered their price target for Qiagen from $55 to $53 per share, citing stable end markets and expectations of gradual improvement ahead. Analyst Commentary Analysts have provided a balanced view of Qiagen's current outlook, highlighting both opportunities and ongoing challenges as the company navigates a gradually improving market environment.

Shared on 15 Nov 25

Fair value Decreased 1.66%

QGEN: Improving Sentiment And Stable Markets Will Set Stage For Future Upside

Analysts have slightly lowered their price target for Qiagen, reducing it by approximately $0.86 to reflect stable end markets. They also acknowledge that improvement is expected as investment sentiment stabilizes.

Shared on 31 Oct 25

Analysts have slightly lowered their price target for Qiagen from $55 to $53, citing stable end markets and anticipated gradual improvements in investment sentiment. Analyst Commentary Recent analyst updates highlight a nuanced outlook for Qiagen, with attention drawn to both its strengths and areas of potential risk in the near term.

Shared on 17 Oct 25

Fair value Decreased 0.28%

Analysts have slightly lowered their price target for Qiagen, reflecting a small decrease from $51.79 to $51.64 per share. They cite ongoing stability in end markets and expectations for gradual valuation improvement.

Shared on 03 Oct 25

Fair value Decreased 1.16%

Analysts have slightly reduced their fair value and price targets for Qiagen, with the consensus moving from approximately $52.39 to $51.79. This change is attributed to stabilizing end markets and expectations of gradual improvement in industry conditions.

Shared on 04 Sep 25

Analysts remain cautiously optimistic on Qiagen, citing modest macroeconomic improvements and solid company execution despite persistent sector headwinds, resulting in an unchanged consensus price target of $52.39. Analyst Commentary Bullish analysts cite modest improvements in macroeconomic conditions, including easing tariff concerns, as supportive of Qiagen's shares.

Shared on 07 May 25

Fair value Increased 6.23%

Shared on 30 Apr 25

Fair value Decreased 0.66%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 23 Apr 25

Fair value Increased 0.12%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 17 Apr 25

Fair value Decreased 0.62%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 09 Apr 25

Fair value Decreased 0.64%

AnalystConsensusTarget has decreased revenue growth from 6.3% to 5.4%.

Shared on 02 Apr 25

Fair value Decreased 6.81%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 26 Mar 25

Fair value Increased 8.71%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 19 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 10 Mar 25

Fair value Increased 0.44%

AnalystConsensusTarget has increased shares outstanding growth rate from 0.0% to 0.0%.

AnalystConsensusTarget Fair Value

US$50.43

9.9% undervalued

Future estimation in

Growth p.a.

Growth p.a.

%

Decrease

Increase

Current revenue growth rate

6.77%

Life Sciences revenue growth rate

0.26%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

%

0

Decrease

Increase

Current discount rate

7.75%

Calculation

US$559.47m

Earnings '28

x

24.70x

PE Ratio '28

=

US$13.82b

Market Cap '28

US$13.82b

Market Cap '28

/

219.03m

No. shares '28

=

US$63.09

Share Price '28

US$63.09 Share Price '28

Discounted to 2025 @ 7.75% p.a.

=

US$50.42

Fair Value '25